Results Participants A total www.selleckchem.com/products/MDV3100.html of 240 of the original 243 participants in the randomized clinical trial were included in the analyses. Three were excluded because they could not actively participate in the trial (one pregnancy prior to initial quit attempt and two moved out of area prior to initial quit attempt). The sample consisted of 167 males and 73 females; 39% of the sample was married, and the majority was Caucasian (78%). Approximately 10% of the sample reported a history of depression. Of the 240 participants, 42 (17.5%) were not able to make a successful 24-hr quit attempt within the 8 weeks of active treatment. Twenty-one (50%) of those unable to make a quit attempt received active treatment (selegiline). The majority (85%) of those in the SQA group achieved 24-hr abstinence at their initial quit date of the treatment study.

Randomized Clinical Trial There were no statistically significant differences between those who received active medication and those who received placebo at either the 8-, 25-, or 52-week follow-ups. Predictors of SQA Table 1 shows the percentage and/or means and SDs for each of the predictor variables measured at baseline and effect sizes for the univariate analyses. In the univariate analyses, mFTQ, F(1, 238) = 4.15, p = .04; �� = 0.35, 95% CI: 0.01�C0.68, the BIS score, F(1, 238) = 8.72, p = .004; �� = 0.50, 95% CI: 0.16�C0.84, and heart rate, F(1, 238) = 6.31, p = .01; �� = 0.43, 95% CI: 0.09�C0.76, were significant predictors of SQA. In the logistic regression model, participants who were successful in their quit attempt had lower mFTQ scores, W (1) = 4.

9, p = .03; OR = 0.85, 95% CI: 0.74�C0.98, higher BIS scores, W (1) = 9.8, p = .002; OR = 1.20, 95% CI: 1.07�C1.35, and lower baseline heart rates, W (1) = 5.1, p = .02; OR = 0.96, 95% CI: 0.93�C0.99, than those unable to quit for at least 24 hr. There were no significant interactions. See Table 2. Table 1. Percentages and/or Means (SDs in parentheses) of Baseline Variables and Effect Sizes for the Univariate Analyses by Successful Versus No SQA Table 2. Logistic Regression Model of Independent Predictors of Successful Quit Attempt and Interactions Predictors of GSK-3 52-Week Abstinence Table 3 shows the percentage and/or means and SDs for each of the predictor variables measured at baseline and effect sizes for the univariate analyses. Gender was the only predictor of abstinence at 1 year with females more likely to be abstinent at the 52-week follow-up than males, ��2 (1) = 4.5, p = .03; OR = 2.00, 95% CI: 1.05�C3.84. No other factors were significant. Table 3.